Embrella Cardiovascular, a developer of embolic protection devices for use during coronary procedures, has closed its series B financing round, raising a total of $6.7 million in new capital.
The Wayne, Pa.-based Embrella said it is developing an embolic protection device, Embrella Embolic Deflector, designed to prevent debris or emboli from entering the brain by deflecting the emboli away from the carotid arteries, which can cause neurological complications during cardiovascular procedures. The Embrella Embolic Deflector could serve as an adjunctive device to be used in procedures, such as the less invasive transcatheter aortic valve implantation procedure. The technology is currently approved in Europe for high-risk patients with severe aortic stenosis.
The financing was led by BioStar Ventures and the MedFocus Fund, who assembled investors, including new investments by Edwards Lifesciences and Hatteras Venture Partners, the company said. In conjunction with the closing, Douglas Reed, MD, general partner of Hatteras, will join the board of directors of Embrella.